BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
4.300
-0.210 (-4.66%)
At close: Apr 28, 2026, 4:00 PM EDT
4.220
-0.080 (-1.86%)
After-hours: Apr 28, 2026, 5:36 PM EDT
BioAtla Revenue
In the year 2025, BioAtla had annual revenue of $2.00M, down -81.82%. BioAtla had revenue of $2.00M in the quarter ending December 31, 2025.
Revenue (ttm)
$2.00M
Revenue Growth
-81.82%
P/S Ratio
3.74
Revenue / Employee
$48,780
Employees
41
Market Cap
7.12M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBCAB News
- 4 weeks ago - BioAtla Announces Share Consolidation - GlobeNewsWire
- 4 weeks ago - BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - GlobeNewsWire
- 2 months ago - BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets - GlobeNewsWire
- 4 months ago - BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - GlobeNewsWire
- 5 months ago - BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - GlobeNewsWire
- 5 months ago - BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - GlobeNewsWire
- 6 months ago - BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas - GlobeNewsWire
- 6 months ago - BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 - GlobeNewsWire